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Abstract
Background: Elevated cardiac troponin, which indicates cardiomyocyte injury, is common after acute ischemic stroke and is
associated with poor functional outcome. Myocardial injury is part of a broad spectrum of cardiac complications that may occur
after acute ischemic stroke. Previous studies have shown that in most patients, the underlying mechanism of stroke-associated
myocardial injury may not be a concomitant acute coronary syndrome. Evidence from animal research and clinical and neuroimaging
studies suggest that functional and structural alterations in the central autonomic network leading to stress-mediated
neurocardiogenic injury may be a key underlying mechanism (ie, stroke-heart syndrome). However, the exact pathophysiological
cascade remains unclear, and the diagnostic and therapeutic implications are unknown.
Objective: The aim of this CORONA-IS (Cardiomyocyte injury following Acute Ischemic Stroke) study is to quantify autonomic
dysfunction and to decipher downstream cardiac mechanisms leading to myocardial injury after acute ischemic stroke.
Methods: In this prospective, observational, single-center cohort study, 300 patients with acute ischemic stroke, confirmed via
cerebral magnetic resonance imaging (MRI) and presenting within 48 hours of symptom onset, will be recruited during in-hospital
stay. On the basis of high-sensitivity cardiac troponin levels and corresponding to the fourth universal definition of myocardial
infarction, 3 groups are defined (ie, no myocardial injury [no cardiac troponin elevation], chronic myocardial injury [stable
elevation], and acute myocardial injury [dynamic rise/fall pattern]). Each group will include approximately 100 patients. Study
patients will receive routine diagnostic care. In addition, they will receive 3 Tesla cardiovascular MRI and transthoracic
echocardiography within 5 days of symptom onset to provide myocardial tissue characterization and assess cardiac function,
20-min high-resolution electrocardiogram for analysis of cardiac autonomic function, and extensive biobanking. A follow-up for
cardiovascular events will be conducted 3 and 12 months after inclusion.
Results: After a 4-month pilot phase, recruitment began in April 2019. We estimate a recruitment period of approximately 3
years to include 300 patients with a complete cardiovascular MRI protocol.
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Conclusions: Stroke-associated myocardial injury is a common and relevant complication. Our study has the potential to provide
a better mechanistic understanding of heart and brain interactions in the setting of acute stroke. Thus, it is essential to develop
algorithms for recognizing patients at risk and to refine diagnostic and therapeutic procedures.
Trial Registration: Clinicaltrials.gov NCT03892226; https://www.clinicaltrials.gov/ct2/show/NCT03892226.
International Registered Report Identifier (IRRID): DERR1-10.2196/24186
(JMIR Res Protoc 2021;10(2):e24186) doi: 10.2196/24186
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Introduction
Background
Elevated cardiac troponin (cTn), which is a sign of myocardial
injury, frequently occurs in the early phase after an acute
ischemic stroke (AIS) and is associated with poor functional
outcome, especially increased mortality [1,2]. Using
high-sensitivity assays, cTn is detectable in more than 90% of
stroke patients; 30%-60% have at least one cTn above the
assay-specific 99th percentile upper reference limit (URL) [2,3].
Approximately 5%-20% show a rise/fall pattern indicating acute
myocardial injury according to the fourth universal definition
of myocardial infarction (MI) [4]. In the latter group, acute
coronary syndrome has to be suspected [4-6]. Following the
American guidelines (American Heart Association/American
Stroke Association), it is specifically recommended to measure
cTn in stroke patients [7,8]. However, recommendations on
how to deal with elevated cTn in the context of AIS remain
vague [8]. Furthermore, expert consensus documents on practical
considerations on the clinical use of cTn list ischemic stroke as
one of the illnesses that leads to clinical uncertainty in the
context of interpretation of elevated cTn [9].
The phenomenon of acute brain injuries (including an ischemic
stroke and intracranial hemorrhage) leading to cardiac
complications, including elevated cardiac enzymes, is known
for a long time. In reference to AIS, it has recently been
described as stroke-heart syndrome (SHS) [10-13]. However,
the exact pathophysiologic background of myocardial injury
(ie, cTn elevation) after stroke is not entirely understood [13,14].
Several hypotheses have been discussed. Besides concomitant
acute MI caused by atherothrombotic coronary artery disease
(type 1 MI), situations of oxygen supply/demand mismatch
have to be considered as underlying reasons. For example,
tachyarrhythmia, hypotension/shock, anemia, or respiratory
failure, which are frequently seen in stroke patients, can lead
to a demand ischemia [4,15]. Furthermore, systemic conditions
such as sepsis or chronic kidney disease may cause or facilitate
myocardial injury [16].
In the TRELAS (Troponin Elevation in Acute Ischemic Stroke)
study, patients with AIS with markedly elevated cTn were
significantly less likely to have a corresponding culprit lesion
on coronary angiography when compared with age- and
sex-matched patients with non-ST elevation acute coronary
syndrome (ACS; showing no significant difference in the degree
of cTn elevation) [17]. Together with the finding that half of
the patients with AIS with markedly elevated cTn had no
coronary artery disease at all, this implies that alternative
mechanisms beyond ACS may play an important role [17]. This
is supported by animal research and clinical and neuroimaging
studies, suggesting that stroke-associated myocardial injury
may originate from structural and/or functional interference
within the central autonomic nervous system (CAN) with an
overshooting sympathetic response [18-20]. On a cellular basis,
it is assumed that excessive catecholamine and cortisol levels
lead to an increased sarcoplasmic calcium influx with a
consecutive hypercontraction of the sarcomeres, electrical
instability, and metabolic and oxidative stress. Consequently,
these pathological mechanisms can induce a contraction band
necrosis and interstitial inflammatory reaction [12,21]. In
summary, elevated troponin levels are frequent, and the
underlying pathologies can be manifold, ranging from
concomitant type 1 MI, demand ischemia, and chronic structural
cardiac disease to systemic conditions. However, especially in
situations with acute cTn elevation after AIS, the CAN seems
to play an important role in the development of myocardial
injury not only by triggering direct myocardial toxicity but also
by facilitating situations of demand ischemia [13,14,22].
Nonetheless, the exact cascade of events remains mostly unclear,
and when it comes to diagnostic procedures and treatment of
affected patients, therapeutic options lack good scientific
evidence [8].
Objective
The aim of the Cardiomyocyte injury following Acute Ischemic
Stroke (CORONA-IS) study is to gain mechanistic insights into
stroke-associated myocardial injury. We intend to provide a
detailed characterization of (1) myocardial tissue; (2)
myocardial, ventricular, and atrial function; and (3) associated




The CORONA-IS study is an investigator-initiated, prospective,
observational, single-center cohort study that aims to include
300 patients with AIS. In November 2018, the Ethics Committee
of the Charité-Universitätsmedizin Berlin, Germany
(EA4/123/18), approved the study. All study procedures are
carried out in accordance with the principles of Good Clinical
Practice and the Declaration of Helsinki. The study was
pre-registered under clinicaltrials.gov, NCT03892226. All
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patients with AIS admitted to the hospital within 48 hours of
symptom onset are listed in a hospital-based registry as part of
an assessment of high-sensitivity cTn (hs-cTn) development in
patients with AIS. All study patients have to fulfill the study
inclusion criteria listed in Textbox 1, and all participants have
to provide written informed consent (for exclusion criteria refer
to Textbox 2).
Textbox 1. Inclusion criteria.
• ability to provide informed consent
• age ≥18 years
• diagnosis of acute ischemic stroke and hospital admission within 48 hours of symptom onset
• visible diffusion-weighted imaging lesion in cerebral magnetic resonance imaging
• repeated measurement of high-sensitivity cardiac troponin within 24 hours of admission
Textbox 2. Exclusion criteria.
• pregnancy or breastfeeding
• impaired renal function (estimated glomerular filtration rate <30 ml/min/1.73 m2)
• contraindications to undergo magnetic resonance imaging (eg, cardiac pacemaker, implantable cardioverter-defibrillator, and cerebral clips)
• persistent or permanent atrial fibrillation (patients with paroxysmal atrial fibrillation will be included if they are in sinus rhythm at admission or
during cardiac monitoring of the stroke unit)
• ST-elevation in electrocardiogram fulfilling criteria of myocardial ischemia
• history of cardiac intervention (eg, coronary artery bypass surgery or percutaneous coronary intervention) within the last 4 weeks
Depending on serial measurements of hs-cTn during the acute
hospital stay (assay characteristics: hs troponin T, Roche
Elecsys, Gen 5; 99th percentile upper reference limit=14 ng/l;
10% coefficients of variation (CV) precision=13 ng/l; limit of
detection=5 ng/l) and according to the fourth universal definition
of MI, 3 groups are defined (Table 1) [4]. We aim to include
100 patients in each group. The cTn values are based on at least
two blood exams: the first one at hospital admission and a
control measurement within 24 hours after admission.
Table 1. Definition of the 3 groups based on patients’ high-sensitivity cardiac troponin values.
hs-cTna values (URLb=14 ng/l)DescriptionGroup
Both hs-cTn levels ≤URLNormal hs-cTn levelsGroup 1
At least one hs-cTn level >URL
but no rise/fall (>20%) in serial measurements
Chronic myocardial injury (elevated but stable cTn levels)Group 2
At least one hs-cTn level >URL
and rise/fall (>20%) in serial measurementsc
Acute myocardial injury (dynamic elevation)Group 3
ahs-cTn: high-sensitivity cardiac troponin.
bURL: upper reference limit (=14 ng/l).
cOr initial cTn value ≤URL and second value >URL+increase >50% URL (ie, 7 ng/l).
In addition to routine clinical procedures (refer to the Baseline
Visit section), study patients receive a baseline assessment, an
additional blood draw for biobanking, 3 Tesla (3T)
cardiovascular magnetic resonance imaging (CMR),
transthoracic echocardiography (TTE), and a 20-min
high-resolution electrocardiogram (ECG) for a comprehensive
assessment of cardiac autonomic function as well as a
questionnaire testing cognitive function and the perception of
stress. Furthermore, 3 and 12 months after discharge, patients
will be followed up via structured telephone interviews for
cardiovascular events and clinical outcomes (Figure 1).
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Figure 1. Study procedure of the Cardiomyocyte injury following Acute Ischemic Stroke study. Patients with a confirmed diagnosis of acute ischemic
stroke via magnetic resonance imaging within 48 hours of symptom onset are eligible for inclusion. Patients receive a baseline visit, transthoracic
echocardiography, 20-min electrocardiogram recording, blood sampling for biobanking, and cognitive testing within the first 2 days after enrolment.
3T cardiovascular magnetic resonance imaging takes place 3-5 days after symptom onset. Telephonic follow-up for cardiovascular events and functional
outcomes will be conducted after 3 and 12 months. CMR: cardiovascular magnetic resonance imaging; d: day; ECG: electrocardiogram; MoCA:
Motreal-Cognitive-Assessment; PSS: Perceived Stress Scale; TTE: transthoracic echocardiography; y: year.
Participants
Patients with a diagnosis of AIS, defined by a
diffusion-weighted imaging lesion on magnetic resonance
imaging (MRI), and hospital admission within 48 hours of
symptom onset are included in the study. The study is carried
out at the Department of Neurology, Charité-Universitätsmedizin
Berlin, Campus Benjamin Franklin, Berlin, Germany.
Baseline Visit
The baseline assessment of the study patients includes
demographics, medical history, medication, and information
about the current stroke (time of symptom onset, time of hospital
admission, and treatment including thrombolysis or
thrombectomy). Stroke severity is classified using the National
Institutes of Health Scale Score. The degree of disability is
assessed using the modified Rankin Scale score. The presence
of chest pain and dyspnea at admission and before the event is
documented. Cognitive function and the individual perception
of stress will be assessed via 2 questionnaires: Perceived Stress
Scale and Montreal-Cognitive-Assessment [23,24]. In addition,
the results of routine diagnostic procedures and stroke unit
monitoring (eg, vital signs, 12-lead ECG, laboratory results,
cerebral computed tomography imaging/MRI, and ultrasound
of the brain-supplying arteries) are recorded.
Cardiovascular MRI Protocol
Patients receive a 3T cardiovascular MRI (CMR). The
examination is performed on a 3T MR scanner (Siemens
Magnetom Prisma fit 3T, Siemens) using ECG for cardiac
gating.
The detailed CMR protocol is depicted in Figure 2. Initially,
for localizing, a half-Fourier acquisition single-shot turbo
spin-echo (HASTE) sequence is conducted. Second, to evaluate
the morphology and function of the left ventricle (LV) and right
ventricle (RV), steady-state free-precession cine images (SSFP)
are acquired during repeated breath-holds. Data are obtained
for 3 long axes (4-chamber [4Ch], 3-chamber [3Ch], and
2-chamber [2Ch] view) and RV (imaging parameters: repetition
time [TR] 45.78 ms, echo time [TE] 1.43 ms, flip angle [FA]
80°, and slice thickness 6.0 mm) and short axes stack—after
contrast media application—to cover the LV (imaging
parameters: TR: 44.80 ms, TE: 1.4 ms, FA: 58°, and slice
thickness 7.0 mm, no gap). Furthermore, after cine long axis,
3 cine short axes (base, middle, and apex) are conducted, serving
as a base for mapping imaging (imaging parameters: TR: 44.80
ms, TE: 1.4 ms, FA: 58°, and slice thickness: 7.0 mm).
Motion-corrected T2 mapping is conducted using a fast
low-angle shot (FLASH) gradient echo sequence in a 4Ch view
and 3 short axis views (SAX) as basal, medial, and apical slices.
T2 maps are based on images with T2 preparation times of
0/30/55 ms, slice thickness of 6.0 mm, TR of 251.49 ms, and
TE of 1.32 ms.
Postcontrast imaging is performed after intravenous injection
of 0.15 mmol/kg body weight Gadobutrol (Gadovist, Bayer
Healthcare). Focal fibrosis imaging (late gadolinium
enhancement [LGE]) is conducted 10 min after Gadobutrol
application. LGE imaging is performed using a phase-sensitive
inversion recovery sequence (PSIR) in the same slice position
as cine imaging (4Ch, 3Ch, and 2Ch view; imaging parameters:
TR: 750.0 ms, TE: 1.55 ms, FA: 20°, and slice thickness: 7.0
mm) as well as full coverage of the LV in a short axis package
(imaging parameters: TR: 1002.4 ms, TE: 1.24 ms, FA: 55°,
and slice thickness: 8.0 mm). TI was adapted to suppress the
myocard.
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Figure 2. 3T cardiovascular magnetic resonance imaging protocol. Workflow of the cardiovascular magnetic resonance imaging sequences conducted.
2Ch: 2-chamber view; 3Ch: 3-chamber view; 4Ch: 4-chamber view; 3T: 3 Tesla; LGE: late gadolinium enhancement; mv: midventricular; SAX: short
axis view; SSPF: steady-state free-precession.
Finally, for further myocardial tissue characterization,
motion-corrected T1 mapping based on the Modified look-locker
inversion recovery technique (MOLLI) using a 3-3-5 pattern is
performed before and 15 min after contrast media application
in 4Ch view and 3 short axes with basal, medial, and apical
slices (imaging parameters: TR: 281.64 ms (4Ch) and 332.67
ms (SAX), TE: 1.12 ms, slice thickness: 6.0 mm, and
Generalized Autocalibrating Partial Parallel Acquisition
(GRAPPA) acceleration factor: 2).
Pseudonymized CMR data are transferred to the core Lab AG
Kardiale MRT (Prof Dr J Schulz-Menger) at the Department of
Cardiology, Charité Campus Buch (Berlin), for further analysis.
Experienced readers (Society for Cardiovascular Magnetic
Resonance level III) analyzing the MR data are blinded to the
clinical data. The clinical results are provided to the study
patient, and in case of pathological findings that require further
diagnostics or treatment, the clinical results are provided to the
patients’ treating physician.
TTE Protocol
Patients undergo TTE on the first day after enrollment. A second
TTE for evaluating dynamic changes in cardiac function is
attempted on the third to fifth day thereafter. Trained physicians
and trained technicians conduct the examination using the
ultrasonic device Vivid T8 (GE Healthcare). The focus of the
examination is the left and right ventricular systolic as well as
diastolic function and morphology. According to the guidelines
of the American Society of Echocardiography, images are
acquired using standard views [25]. The TTE protocol includes
two-dimensional imaging, M-mode measurements, color
Doppler imaging and spectral Doppler imaging
(continuous-wave [CW], pulsed-wave [PW], and Doppler tissue
imaging [DTI]), as well as strain imaging using a
2D-speckle-tracking technique. Systolic LV function will be
defined according to the recommendations for cardiac chamber
quantification by echocardiography in adults as normal range
(left ventricular ejection fraction [LV EF] 52%-72%
[male]/54%-74% [female]), mildly abnormal (42%-51%
[male]/41%-53% [female]), moderately abnormal (30%-40%),
and severely abnormal (<30%) [26]. Values of signs suggesting
pathologic RV systolic function are defined as TAPSE (tricuspid
annular plane systolic excursion) <17 mm and s’ velocity <9.5
cm/s [27]. In addition, diastolic function will be evaluated
according to the criteria of the Heart Failure Association of the
European Society of Cardiology [28]. An independent rater
blinded to clinical information will evaluate the
echocardiographic data.
Autonomic ECG Markers
In addition to routine 12-lead ECG at admission and stroke unit
monitoring, included patients receive an additional 20-min
high-resolution resting ECG during the first day after enrollment
using the portable medilog AR4+ device (Schiller AG). The
aim is to measure specific autonomic markers periodic
repolarization dynamics (PRD) and deceleration capacity (DC),
reflecting sympathetic and vagal components of cardiac
autonomic function in addition to standard measures of heart
rate variability (HRV) in time and frequency domain [29-31].
The 7 electrodes of the high-resolution ECG are applied
according to the Frank lead configuration in the 3 orthogonal
axes X, Y, and Z. The examination is performed under
standardized conditions (supine position, patient is not allowed
to talk or change the position during the recording). For analysis,
the pseudonymized ECG data are transmitted to the core lab of
the academic working group biosignal analysis (Prof Dr A
Bauer) at the cardiology department of the Medical University
of Innsbruck, Austria. Members of the working group analyzing
the data are blinded to all clinical information.
Biobanking
The study protocol includes an additional blood examination
for biobanking to allow future study of further potential
mechanisms. Blood drawing takes place during the first day
after enrollment and includes 2 EDTA (for both whole blood
and plasma samples), 1 heparin, 1 coagulation sodium citrate,
and 1 serum tube. Blood withdrawal, centrifugation, and
processing will be conducted by a trained study nurse. Blood
samples are transferred to the Central Biomaterial Bank Charité
for management and storage. After processing, the stored
samples consist of 5.7 mL of EDTA whole blood; 1.5 mL of
citrate plasma; and 2 mL of EDTA plasma, heparinized plasma,
and serum samples each. These samples will allow measurement
of various potential biomarkers of interest. Dependent on further
funding, we consider to determine biomarkers of cardiac injury
and stress, proinflammatory markers, and markers of endothelial
dysfunction (such as N-terminal B-type natriuretic peptide
[NT-proBNP], midregional proatrial natriuretic peptide
[MRproANP], Copeptin, interleukin-6, interleukin-1β, Soluble
suppression of tumorigenicity 2 [sST2], and monocyte
chemoattractant protein-1 [MCP-1]). Furthermore, we consider
exploring whether patients with signs of stroke-associated
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myocardial injury present distinct miRNA-pattern. Finally, the
design allows future cooperation with other research groups.
Follow-Up Telephone Interview
A follow-up regarding major cardiovascular events takes place
3 and 12 months after enrollment via telephone interview and
is conducted by a trained participant of the research group. A
major cardiovascular event is defined as the occurrence of
transient ischemic attack and ischemic stroke, intracranial
hemorrhage, MI, coronary artery bypass surgery or percutaneous
coronary intervention, new atrial fibrillation, hospitalization for
heart failure, and death. The functional outcome is assessed
using the modified Rankin Scale. In case of death, the date of
death is recorded using information from registration offices.
In the case of cardiovascular events, medical records will be
requested from the treating physician/institution. Furthermore,
Charité records will be screened for readmission or further
treatment. In case of unclear loss to follow-up, mortality status
will be retrieved from the residents’ registration office.
Study Outcomes
Our main hypothesis is that the development of stroke-associated
myocardial injury in patients with AIS is based on a
stroke-related interference in the CAN resulting in myocardial
tissue alterations and dysfunction (ie, stroke-induced
"myocardial stunning") [13]. Using a systemic and multimodal
diagnostic approach, we aim to provide a detailed
characterization of myocardial tissue, cardiac function, and
autonomic cardiac regulation (Figure 3). Thus, outcome
measures are primarily based on cardiac tissue characterization
via CMR, functional assessment using TTE and CMR
measurements, and values of specific autonomic ECG markers.
Textbox 3 shows the detailed outcome measures. In summary,
as we assume that patients with stroke-associated myocardial
injury show a Takotsubo syndrome (TTS)/stress cardiomyopathy
pattern of lesions in the myocardium, we will focus on the
presence of wall motion abnormalities together with myocardial
edema (T2 mapping) but without corresponding LGE in CMR
[32,33]. Left ventricular dysfunction and wall motion
abnormalities will be measured via cine imaging in CMR and
TTE. As a correlate of chronic myocardial injury, we further
assess myocardial fibrosis/scar via LGE, diffuse fibrosis via T1
mapping, and extracellular volume fraction (ECV%) [34]. To
facilitate the differentiation between stroke-induced and
coronary-mediated myocardial injury, we evaluate typical CMR
signs suggesting a recent MI (ie, presence of co-occurring LGE
and acute edema in CMR). Infarcted myocardium will be
defined as a region with a mean signal intensity >5SDs relative
to the remote uninjured myocardium on LGE images [35].
Figure 3. Diagnostic assessment of the Cardiomyocyte injury following Acute Ischemic Stroke study. Illustration of the target points of the multimodal
diagnostic workup to provide a thorough phenotyping of patients with stroke-associated myocardial injury. cMRI: cerebral magnetic resonance imaging;
ECG: electrocardiogram; MRI: magnetic resonance imaging; TTE: transthoracic echocardiography.
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Textbox 3. Study endpoints.
Primary outcome measures
• Frequency of Takotsubo syndrome pattern on cardiovascular magnetic resonance imaging (CMR); consisting of wall motion abnormalities
together with myocardial edema (T2 mapping) but without late gadolinium enhancement
• Frequency and extent of myocardial edema
• Frequency of recent myocardial infarction on CMR
• Frequency and extent of ischemic and nonischemic myocardial fibrosis according to late gadolinium enhancement imaging and according to
extracellular volume fraction on T1 mapping
• Frequency of left ventricular dysfunction in CMR (ie, ejection fraction and end diastolic left ventricular volume)
• Frequency of impaired left ventricular systolic and diastolic function in the transthoracic echocardiography
Secondary outcome measures
• Frequency of pathologic values of Periodic Repolarization Dynamics (PRDs) and Deceleration Capacity (DC; PRD≥5.75 deg²; DC≤2.5 ms)
• Frequency of values corresponding to high perceived stress in the Perceived Stress Scale (values ranging from 27 to 40)
• Frequency of cardiovascular events after 3 and 12 months
• Functional outcome after 3 and 12 months assessed using the modified Rankin Scale.
Sample Size Calculation and Statistical Analysis
Regarding the primary hypothesis and based on the published
literature, we expect a rate of acute myocardial edema on T2
mapping in CMR in approximately 15% of patients with acute
myocardial injury [17,36]. In the comparison groups with no
or chronic myocardial injury, we expect a significantly lower
rate (approximately 2%) presenting with acute myocardial
edema [37].
To show a significant difference between the groups (two-sided
α=.05), a sample size of 48 patients per group is required to
reach a power of 80% and 89 patients per group for a power of
90%. Taking into consideration that in previous studies, due to
impaired compliance or technical problems, the complete
protocol of CMR could be realized only in approximately 85%
of the study patients, we aim to include approximately 100-105
patients in each group.
Group comparisons (when comparing between the 3 groups) of
the primary and secondary outcome measures (frequencies of
specific alterations in CMR, TTE, and ECG) will be conducted
using the chi-square test for categorical variables and, in case
of continuous variables, using one-way analysis of variance or
Kruskal-Wallis test, as appropriate. When comparing 2 groups
(group 3 vs group 1 or group 3 vs group 2), Student t test will
be used to compare continuous data. Logistic regression analyses
will be used to calculate odds ratios and 95% CI to examine the
association between elevated hs-cTn levels and the presence of
specific structural and functional cardiac alterations in CMR
and TTE. Multiple regression analyses using backward selection
will be used to identify factors associated with certain
myocardial alterations or ECG findings.
Results
Screening started in January 2019. After the initial pilot phase,
the first patient was enrolled in April 2019. We estimate a
recruitment period of approximately 3 years to enroll 300
patients with the complete CMR protocol. At the time of
submission, 107 patients had been included. The final results
are expected in 2023.
Discussion
Overview
This prospective, observational CORONA-IS study aims to
clarify the underlying pathobiology of stroke-associated
myocardial injury. The observation that patients with acute,
severe neurological events often develop cardiac complications
is well known and has been described as SHS or brain-heart
syndrome [13]. Although there are strong indicators, suggesting
that a stroke-induced dysregulation of the CAN leads to
functional and structural cardiac alterations, many aspects of
the pathophysiology remain unknown, and so far, no diagnostic
or therapeutic algorithms for the treatment of these patients are
available. Therefore, the aim of the CORONA-IS study is to
explore and clarify the pathway from the brain to the heart,
focusing on the crucial role of the autonomic nervous system
and the cardiac phenotype.
The first goal is to visualize downstream cardiac mechanisms
using CMR and TTE. We expect stroke patients with acute
myocardial injury to show a higher rate and a different pattern
of myocardial edema than patients with normal cTn. More
precisely, we expect a myocardial edema (in T2 mapping in
CMR) with wall motion abnormalities but without LGE [36,38].
This combination of edema without LGE is also seen in TTS,
a condition that is in turn associated with an increased
sympathetic stimulation [39]. TTS typically occurs following
an emotionally or physically triggering event, but it can also
develop after an acute neurologic illness [40]. In addition, we
aim to assess alterations suggesting an acute or recent MI in the
different groups. So far, several studies have applied CMR in
stroke patients but mostly as part of a diagnostic workup to
determine possible cardioembolic etiology in cryptogenic stroke
[41-43]. For example, the HEBRAS (HEart and BRain interfaces
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in Acute ischemic Stroke) study will determine whether an
enhanced diagnostic MRI workup (including CMR) combined
with prolonged Holter monitoring will increase the detection
rate of pathologic cardiac findings in patients with AIS [44].
To date, myocardial tissue characterization in patients with
stroke-associated myocardial injury has not been investigated
via CMR.
Besides structural alterations of the myocardium, we further
aim to clarify whether patients with AIS and stroke-associated
myocardial injury show—especially transient—functional
cardiac alterations. Cardiac dysfunctions, including wall motion
abnormalities or reduced EF, are often seen in patients with
ischemic stroke and other acute severe neurologic conditions
[1,45,46]. Regarding our study population, we expect to see
higher rates of changes in left ventricular systolic and diastolic
functions in patients with dynamic troponin elevation.
The second aim of the study is to investigate the role of CAN
in the development of stroke-associated myocardial injury.
There are different ways to display the influence of CAN on
the cardiovascular system. Invasive diagnostic methods with
direct recording of neural activity are not feasible in clinical
settings. Noninvasive methods include for instance measurement
of baroreceptor sensitivity or HRV. Reduced HRV and impaired
baroreceptor sensitivity are associated with higher stroke
severity and worse clinical outcomes [47,48]. However, these
diagnostic tools represent only the combined sympathetic and
parasympathetic influence on the cardiovascular system. There
is evidence that increased sympathetic nervous activity can lead
to destabilization of the myocardial repolarization phase [49].
In the CORONA-IS study, we will use the novel ECG markers,
PRD, and DC. PRD assesses rhythmic modulations of cardiac
repolarization in the low-frequency spectral range (≤0.1 Hz)
[31,50]. Experimental and clinical evidence suggests that these
low-frequency alterations are caused by phasic efferent
sympathetic activity. DC is an integral measure of
deceleration-related oscillations of the heart rate and primarily
reflects parasympathetic activity [51]. PRD alone and in
combination with DC have been shown to be a strong and
independent predictor of sudden cardiac death in patients with
MI [30,31,52]. To date, these markers have not been investigated
in patients with AIS. They could provide important information
regarding the assumed dysfunction of the CAN causing
stroke-associated myocardial injury. It has to be kept in mind
that these noninvasive measures can only serve to display an
association between altered autonomic cardiac control and the
presence of myocardial injury in stroke patients. To show a
direct causation, further studies with nonobservational designs
will be necessary. As the clinical differentiation between
concomitant MI and stroke-associated myocardial injury is
difficult, we aim to investigate whether specific biomarkers can
help distinguish between both conditions. Therefore, we conduct
thorough biobanking to evaluate the role of various potential
biomarkers.
Limitations
Some limitations of the study will need to be considered. First,
as the aim of CORONA-IS is to investigate patients with
stroke-associated myocardial injury (ie, SHS), it is necessary
to avoid including patients with clearly coronary-mediated
myocardial ischemia. Hence, patients with signs of a
concomitant or recent MI (ie, typical alterations in the ECG,
such as ST elevations or a new left bundle branch block, as well
as a recent coronary artery bypass surgery or percutaneous
coronary intervention) will be excluded. Second, as CMR and
the assessment of autonomic ECG markers depend on a rhythmic
heartbeat, patients with persistent or permanent atrial fibrillation
will not be included, even though they may be prone to develop
stroke-associated myocardial injury. Third, specific
contraindications to undergo CMR (eg, certain metallic implants,
claustrophobia, or physiologic constitution such as severe
obesity or an inability to stay in the supine position) may lead
to an underrepresentation of these patients in the study. To
correct for potential selection bias in the final analysis, the
screen log of the study will be analyzed at the end of data
collection to assess whether the rate of excluded patients due
to CMR contraindications differed among the 3 groups. Finally,
considering the necessity of giving informed consent to
participate in the CORONA-IS trial, patients with large
infarctions and aphasia may also be underrepresented.
Conclusions
In summary, the CORONA-IS study aims to provide a deep
phenotyping of patients with stroke-associated myocardial injury
by using different diagnostic tools, such as 3T CMR, TTE,
specific novel autonomic ECG markers, and different blood
biomarkers. The goal of this prospective, observational study
is to develop a better understanding of the characteristics and
the pathophysiology of stroke-associated acute myocardial
injury (SHS) to identify patients at risk and improve diagnostic
and therapeutic procedures.
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ACS: acute coronary syndrome
AIS: acute ischemic stroke
CAN: central autonomic nervous system
CMR: cardiovascular magnetic resonance imaging
CORONA-IS: Cardiomyocyte injury following Acute Ischemic Stroke
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HRV: heart rate variability
hs-cTn: high-sensitivity cTn
LGE: late Gadolinium enhancement
LV: left ventricle
MI: myocardial infarction
MRI: magnetic resonance imaging
PRD: periodic repolarization dynamics
RV: right ventricle
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